tetano
Editor, Senior Moderator
J Leukoc Biol
. 2021 Nov 3.
doi: 10.1002/JLB.4COVA0121-084RR. Online ahead of print.
Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation
Amanda N Pinski[SUP] 1 2 3 [/SUP], Tara L Steffen[SUP] 4 [/SUP], Michael Z Zulu[SUP] 1 2 3 [/SUP], Sarah L George[SUP] 5 [/SUP], Alexandria Dickson[SUP] 4 [/SUP], Delia Tifrea[SUP] 6 [/SUP], Kevin J Maroney[SUP] 1 [/SUP], Neil Tedeschi[SUP] 7 [/SUP], Yun Zhang[SUP] 7 [/SUP], Richard H Scheuermann[SUP] 7 [/SUP], Amelia K Pinto[SUP] 4 [/SUP], James D Brien[SUP] 4 [/SUP], Ilhem Messaoudi[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease-2019 (COVID-19), a respiratory disease that varies in severity from mild to severe/fatal. Several risk factors for severe disease have been identified, notably age, male sex, and pre-existing conditions such as diabetes, obesity, and hypertension. Several advancements in clinical care have been achieved over the past year, including the use of corticosteroids (e.g., corticosteroids) and other immune-modulatory treatments that have now become standard of care for patients with acute severe COVID-19. While the understanding of the mechanisms that underlie increased disease severity with age has improved over the past few months, it remains incomplete. Furthermore, the molecular impact of corticosteroid treatment on host response to acute SARS-CoV-2 infection has not been investigated. In this study, a cross-sectional and longitudinal analysis of Ab, soluble immune mediators, and transcriptional responses in young (65 ≤ years) and aged (≥ 65 years) diabetic males with obesity hospitalized with acute severe COVID-19 was conducted. Additionally, the transcriptional profiles in samples obtained before and after corticosteroids became standard of care were compared. The analysis indicates that severe COVID-19 is characterized by robust Ab responses, heightened systemic inflammation, increased expression of genes related to inflammatory and pro-apoptotic processes, and reduced expression of those important for adaptive immunity regardless of age. In contrast, COVID-19 patients receiving steroids did not show high levels of systemic immune mediators and lacked transcriptional indicators of heightened inflammatory and apoptotic responses. Overall, these data suggest that inflammation and cell death are key drivers of severe COVID-19 pathogenesis in the absence of corticosteroid therapy.
Keywords: COVID19; SARS-CoV-2; antibodies; comorbidity; corticosteroid; inflammation; male; transcriptional.
. 2021 Nov 3.
doi: 10.1002/JLB.4COVA0121-084RR. Online ahead of print.
Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation
Amanda N Pinski[SUP] 1 2 3 [/SUP], Tara L Steffen[SUP] 4 [/SUP], Michael Z Zulu[SUP] 1 2 3 [/SUP], Sarah L George[SUP] 5 [/SUP], Alexandria Dickson[SUP] 4 [/SUP], Delia Tifrea[SUP] 6 [/SUP], Kevin J Maroney[SUP] 1 [/SUP], Neil Tedeschi[SUP] 7 [/SUP], Yun Zhang[SUP] 7 [/SUP], Richard H Scheuermann[SUP] 7 [/SUP], Amelia K Pinto[SUP] 4 [/SUP], James D Brien[SUP] 4 [/SUP], Ilhem Messaoudi[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 34730254
- DOI: 10.1002/JLB.4COVA0121-084RR
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease-2019 (COVID-19), a respiratory disease that varies in severity from mild to severe/fatal. Several risk factors for severe disease have been identified, notably age, male sex, and pre-existing conditions such as diabetes, obesity, and hypertension. Several advancements in clinical care have been achieved over the past year, including the use of corticosteroids (e.g., corticosteroids) and other immune-modulatory treatments that have now become standard of care for patients with acute severe COVID-19. While the understanding of the mechanisms that underlie increased disease severity with age has improved over the past few months, it remains incomplete. Furthermore, the molecular impact of corticosteroid treatment on host response to acute SARS-CoV-2 infection has not been investigated. In this study, a cross-sectional and longitudinal analysis of Ab, soluble immune mediators, and transcriptional responses in young (65 ≤ years) and aged (≥ 65 years) diabetic males with obesity hospitalized with acute severe COVID-19 was conducted. Additionally, the transcriptional profiles in samples obtained before and after corticosteroids became standard of care were compared. The analysis indicates that severe COVID-19 is characterized by robust Ab responses, heightened systemic inflammation, increased expression of genes related to inflammatory and pro-apoptotic processes, and reduced expression of those important for adaptive immunity regardless of age. In contrast, COVID-19 patients receiving steroids did not show high levels of systemic immune mediators and lacked transcriptional indicators of heightened inflammatory and apoptotic responses. Overall, these data suggest that inflammation and cell death are key drivers of severe COVID-19 pathogenesis in the absence of corticosteroid therapy.
Keywords: COVID19; SARS-CoV-2; antibodies; comorbidity; corticosteroid; inflammation; male; transcriptional.